Novo Nordisk Founded in Denmark, Novo Nordisk traces its roots back to the 1920s discovery of insulin. It became today’s Novo Nordisk via a 1989 merger of two early insulin-makers. Today Novo is best known for its blockbuster GLP-1 drugs: weekly injections like Ozempic (semaglutide for type 2 diabetes) and Wegovy (higher-dose semaglutide for obesity). Over the past few years, they rode the wave of skyrocketing obesity rates and shifting attitudes toward weight loss. This led to a surge in sales and global demand. Novo Nordisk was also Europe’s most valuable company at one point. The Rise: How Semaglutide Changed the Game Mechanism: Semaglutide mimics an intestinal hormone to boost insulin release and supress appetite. Blockbuster launch: Ozempic (for type 2 diabetes) broke $10 billion in sales within its first two years. Wegovy (for obesity) doubled in sales year-over-y...
Aims to provide an impeccable, unique, and creative website that suits your brand image and requirements.